Health Care Supplies

Sanara Medtech

Sanara Medtech released FY2026 Q1 earnings on May 11 Pre-Market (EST), actual revenue USD 27.8 M (forecast USD 26.8 M), actual EPS USD 0.0467 (forecast USD -0.13)

Sanara Medtech to release FY2026 Q1 earnings on May 12 Pre-Market EST, forecast revenue USD 26.8 M, EPS USD -0.13

Sanara Medtech released FY2025 Q4 earnings on March 24 Pre-Market (EST), actual revenue USD 27.55 M (forecast USD 27.4 M), actual EPS USD -0.19 (forecast USD 0.11)

Sanara Medtech released FY2025 earnings on March 24 Pre-Market (EST), actual revenue USD 103.12 M (forecast USD 102.97 M), actual EPS USD -4.3611 (forecast USD 0.2)

Sanara Medtech to Release FY2025 Q4 Earnings on March 24, Pre-Market EST; Forecast Revenue USD 27.4 M, EPS USD 0.11

Sanara Medtech released FY2025 9 Months Earnings on November 12 Pre-Market (EST), actual revenue USD 75.6 M, actual EPS USD -4.0502

Sanara Medtech released FY2025 Q3 earnings on November 12 Pre-Market EST, actual revenue USD 26.33 M (forecast USD 26.63 M), actual EPS USD -3.4048 (forecast USD -0.215)

Sanara Medtech to Release FY2025 Q3 Earnings on November 12, Pre-Market EST; Forecast Revenue USD 26.63M, EPS USD -0.215

Sanara Medtech released FY2025 Q2 earnings on August 13 Pre-Market (EST), actual revenue USD 25.83 M (forecast USD 25.15 M), actual EPS USD -0.2338 (forecast USD -0.44)

Sanara Medtech released FY2025 Semi-Annual earnings on August 13 Pre-Market (EST), actual revenue USD 49.26 M, actual EPS USD -0.6449

Sanara Medtech to Release FY2025 Q2 Earnings on August 13 Pre-Market EST, Forecast Revenue USD 25.15 M, EPS USD -0.44

Sanara MedTech Inc. Insiders Hold 31% Stake

Sanara MedTech Updates Post Annual General Meeting and Analyst Ratings

H.C. Wainright raises SANARA MEDTECH target price to $53

Sanara Medtech Inc reports Q1 EPS loss of 41 cents

Sanara Medtech released FY2025 Q1 earnings on May 14 Pre-Market EST, actual revenue USD 23.43 M (forecast USD 23.48 M), actual EPS USD -0.4115 (forecast USD -0.505)

Sanara Medtech Inc Expects EPS Loss of 50 Cents

Sanara Medtech to Release FY2025 Q1 Earnings on May 14 Pre-Market EST, Forecast Revenue USD 23.48 M, EPS USD -0.505

Sanara MedTech Inc. reports better-than-expected quarterly earnings but sees share price drop

Sanara MedTech Inc. Plans to Release Q1 2025 Earnings Report

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

SMTI

ATYR

ERNA

In Tuesday's intraday session, Ernexa Therapeutics (NASDAQ:ERNA) saw a significant gain of 79.4%, reaching $12.94, while USBC (AMEX:USBC) rose by 55.72% to $0.79. Other notable gainers included Sanara MedTech (NASDAQ:SMTI) up 30.21%, and PACS Group (NYSE:PACS) up 26.47%. Conversely, Tyr Pharma (NASDAQ:ATYR) experienced a decline of 27.4%, followed by CEL-SCI (AMEX:CVM) down 25.89%. The Q1 earnings reports for several companies were released yesterday, impacting stock movements.

benzinga_article

ATYR Pharma

Ernexa Therapeutics

PACS

USBC

CEL-SCI

SPDR S&P Biotech

iShares Global Healthcare

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

iShares Biotechnology ETF

Direxion S&P Biotech Bear 3X

First Trust NYSE Arca Biotech Index Fd

iShares US Healthcare Providers

Invesco Biotechnology & Genome ETF

SPDR S&P Health

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

VG Health

Invesco Nasdaq Biotechnology ETF

Alpha Compute

Macrogenics

WORK Medical Tech

Akari Therap

CVRx

Harrow

Harrow Health Pref Share HROWM 11.875 12/31/27

Harrow Health Pref Share HROWL 8.625 04/30/26

12 Health Care Stocks Moving In Tuesday's Intraday Session

Sanara MedTech shares are trading higher after the company reported better-than-expected Q1 financial results.

Sanara MedTech (NASDAQ:SMTI) reported a 19% revenue increase for Q1 2026, achieving GAAP net profitability with a net income of $0.4 million. The company expanded its sales team to 43 representatives and increased its market presence in over 4,000 hospitals. Q2 2026 revenue is expected to be between $28.5 million and $29.5 million, maintaining full-year guidance of $116 million to $121 million. Management emphasized a strategic focus on the surgical market and plans for organic growth, including a new product launch in 2027.

Transcript: Sanara MedTech Q1 2026 Earnings Conference Call

Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited) | SMTI Stock News

StockTitan

Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited) | SMTI Stock News

In Valencia, California on May 6, 2026, Med Tech Solutions (MTS), a prominent player in managed healthcare IT services, disclosed their acquisition of Avarion, a renowned HIT Advisory firm that has been awarded Best in KLAS two times. Avarion primarily caters to hospitals, health systems, and care networks. This strategic move is aimed at enhancing MTS's capabilities and expanding their market share in the industry.

Unusual Whales

Medtronic

iShares US Medical Devices

SPDR S&P Health Equip

Med Tech Solutions Acquires Avarion, Strengthening Its Role as a Managed Service Provider Across the Full Care Continuum

Sanara MedTech (NASDAQ: SMTI) is set to release its Q1 2026 earnings on May 12, with analysts predicting a loss of $0.13 per share and revenue of $26.80 million. The company previously reported earnings of $0.04 per share, missing estimates. Institutional investors have increased their stakes, and analysts have mixed ratings on the stock, with an average rating of "Hold" and a target price of $34.00. Sanara MedTech specializes in medical technology for ENT healthcare, focusing on innovative sinus dilation systems.

Market Beat

BNP Paribas

Wells Fargo

Lazard

Deutsche Bank AG

Bank of America

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Sanara MedTech (SMTI) Projected to Post Earnings on Tuesday

Pomerantz Law Firm is investigating claims on behalf of investors of Sanara MedTech, Inc. (NASDAQ: SMTI) regarding potential securities fraud or unlawful business practices by the company and its officers. This follows Sanara's announcement of discontinuing its Tissue Health Plus program, leading to a reported net loss of $31.2 million and a significant drop in stock price by 24.7% to $21.11 per share. Investors are encouraged to contact Pomerantz for more information about joining the class action.

prnewswire

21:42 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI

STAA

ASXC

Reach Surgical, a division of Genesis MedTech, has received CE Mark approval for its iREACH IRIS, the first powered reusable stapler featuring Real-Time Firing Curve™ and 90° articulation. This innovative device provides surgeons with real-time insights into tissue behavior during procedures, enhancing surgical judgment and reducing complications like anastomotic leaks. The iREACH IRIS is designed for single-patient use, streamlining workflow and minimizing cross-contamination risks. It aims to improve surgical outcomes in various procedures, including colorectal and thoracic surgeries, by offering better access and precision control.

STAAR Surgical

AJJ Medtech

Asensus Surgical

Vicarious Surgical

23:30 ETReach Surgical Receives CE Mark Approval for iREACH IRIS, First Powered Reusable Stapler with Real-Time Firing Curve™ and 90° Articulation

Sanara Medtech(SMTI.US)

12 Health Care Stocks Moving In Tuesday's Intraday Session

Sanara MedTech shares are trading higher after the company reported better-than-expected Q1 financial results.

Transcript: Sanara MedTech Q1 2026 Earnings Conference Call

Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited) | SMTI Stock News

Med Tech Solutions Acquires Avarion, Strengthening Its Role as a Managed Service Provider Across the Full Care Continuum

Sanara MedTech (SMTI) Projected to Post Earnings on Tuesday

21:42 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI

23:30 ETReach Surgical Receives CE Mark Approval for iREACH IRIS, First Powered Reusable Stapler with Real-Time Firing Curve™ and 90° Articulation